科研之友
微信
新浪微博
Facebook
分享链接
摘要
Purpose: Our aim is to evaluate the use of combined bevacizumab with 5-Fluorouracil (5-FU) on post-operative scarring survival following experimental skin incision surgery in comparison to the agents alone.
Material and methods: Skin incision surgery was performed on 28 female Spraque-Dawley rats. The rats were allocated to one of four treatments: 5-FU combined with Bevacizumab, 5FU alone, bevacizumab alone and phosphate buffered saline (PBS). A single subcutaneous injection was administered immediate postoperatively. Histological staining determined the presence of cutaneous fibrosis and mRNA expression of collagen I and fibronectin in the tissue was quantified.
Results: Relative quantity of Colla1 mRNA transcript 5 fold increased in Group 1 (PBS) in comparison to control group. However, Colla1 level in Group 2 (5-FU) and 3 (bevacizumab) is decreased. The lowest level of Colla1 was detected in Group 4 (combination of 5-FU and bevacizumab). On the other hand, relative quantity of Fn1 is slightly elevated in Group 1 (PBS) and decreased in Group 2 (5-FU) and group 3 (bevacizumab) in comparison to control group. The lowest level of Fn 1 was detected in Group 4 (combination of 5-FU and bevacizumab).
Conclusions: Bevacizumab in combination with 5-FU resulted in a greater anti-fibrotic effect compared to monotherapy with 5FU or bevacizumab alone, as evidenced by the attenuation in fibronectin and mature collagen I expression and deposition. (P<0.05) The results provide compelling evidence that combined bevacizumab and 5-FU offers superior anti-fibrotic effect over monotherapy. A synergistic effect is suggested to be present.
- 出版日期2012
